Drug Profile
C-peptide - Eli Lilly and Company
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Nonindustrial source
- Class Pancreatic hormones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic nephropathies; Diabetic neuropathies; Type 1 diabetes mellitus